ArticlePharmacoepidemiology and drug safety2023
Mobile apps for quick adverse drug reaction report: A scoping review.
Article in Pharmacoepidemiology and drug safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Adverse drug reaction reporting with the Med Safety app in Uganda: a cluster-randomised, controlled trial.The Lancet. Global health · 2025Trial
- Article
- When does Follow-up on Adverse Events Improve the Understanding of Medicine and Vaccine Safety? Insights from Global Expert Perspectives.Drug safety · 2026Article
- Design and Evaluation of a Gamification-Based Mobile Application for Reporting Adverse Drug Reactions by Patients and Healthcare Professionals: A Pilot Usability Study in Diabetes Care.Drug, healthcare and patient safety · 2026Article
- Article
- Underreporting of Adverse Events Following COVID-19 Vaccination Among Healthcare Professionals in Poland: Potential Implications for Vaccine Hesitancy.Tropical medicine and infectious disease · 2025Article
- Real-World Complexity of Prescribing Cascades.Basic & clinical pharmacology & toxicology · 2025Review
- Employing bibliometrics and natural language processing (NLP) to analyse real-world applications of adverse drug reaction.Exploratory research in clinical and social pharmacy · 2025Article
- A scoping review and expert consensus on digital determinants of health.Bulletin of the World Health Organization · 2025Article
- Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study.Cancer immunology, immunotherapy : CII · 2024Article
- Enhancing Pharmacovigilance in Côte d'Ivoire: Impact of GSK's Training and Mentoring Pilot Project in the Abidjan Region.Drug safety · 2024Article
- Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A Prospective Study of Active Pharmacovigilance.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Impact of multifaceted interventions on the knowledge, attitude, and practice of adverse drug reactions reporting among healthcare workers in Vietnam: a comparative intervention study.Frontiers in pharmacology · 2024Article
- Alternate day versus consecutive day oral iron supplementation in iron-depleted women: a randomized double-blind placebo-controlled study.EClinicalMedicine · 2023Article
- Under-reporting of gastrointestinal bleeding associated with anticoagulant use using the UK Yellow Card Scheme.International journal of clinical pharmacy · 2023Article
- Reporting, Monitoring, and Handling of Adverse Drug Reactions in Australia: Scoping Review.JMIR public health and surveillance · 2023Article
- Mobile apps for quick adverse drug reaction report: A scoping review.Pharmacoepidemiology and drug safety · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSpontaneous notification systems are essential in a post-marketing safety context. However, using this method, only about 6% of all adverse drug reactions are notified. To overcome this sub-notification problem, new methods need to be developed to improve and facilitate reporting. In this sense, the use of digital media, mainly medical mobile apps, has been presented as a powerful tool, including in pharmacovigilance. We performed a scope review to identify the available apps used to report adverse drug reactions around the world to eventually identify which of them best fits the Portuguese pharmacovigilance system.
methodsThe Joanna Briggs Institute guidelines were considered, and the framework proposed by Arksey and O'Malley was followed. All the articles that met the inclusion criteria were examined for this review. When the studies lacked in information about the app, Google was used to enhance the search for further information.
resultsA final number of five articles were included, revealing seven implemented mobile apps for adverse drug reaction report (Medwatcher, VigiBIP, Yellow Card, Bijwerking, Halmed, Med Safety, and ADR PvPi). These apps are implemented in the United States, France, United Kingdom, The Netherlands, Croatia, and India. Med Safety was originally designed for multi-region use and is implemented in 12 low and middle-income countries.
conclusionsApps are easier and faster ways of reporting. The integration of such a tool in an individual care plan would allow to maintain a complete electronic health record at both individual and global level and could be eventually seen as an added value by both health professionals and patients. A country specific version of the WEB-RADR could be a solution for Portugal, in order to introduce an app to notify ADRs at the national level, due previous successful experiences in European countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.